I thought this is very significant on page 3:
"
However, exploratory information from the Open Label extension phase suggests that for the cohort of 27 trial participants that completed all 24 months (11 from 15 that started IMAGINE on placebo together with 16 of 25 that remained on PBT2 for the 24 months), the amyloid levels decreased in this cohort compared to an historical control group from the Australian Imaging Biomarker and Lifestyle (AIBL) study. Although exploratory, the cohort data encourages exploration of changing brain amyloid in larger well powered trials "
Looks like they are seeing benefits in the extension trial results ... Looking forward to the paper !
I thought this is very significant on page 3: " However,...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $886 | 275.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 56368671 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125986200 | 26 |
View Market Depth
| Last trade - 11.34am 30/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |